Obstetrics and Gynecology International / 2010 / Article / Tab 2

Review Article

Molecular Profiling of Endometrial Malignancies

Table 2

Genetic alterations of type I and type II endometrial carcinomas, reported in percentages (references).

Type IType II

PTEN inactivationUp to 83% [1, 4, 11, 12]11% [1, 2, 12]
PIK3CA mutation26–36% [7, 9]5% [7]
KRAS mutation10–30% [1, 2, 4, 712, 17]0–10% [2, 12]
-catenin /CTNNB1 mutation14–44% [7, 8]0–5% [1, 7, 10, 11]
Microsatellite instability20–45% [1, 710]0–11% [8, 9]
p53 mutation10–20% [1, 4, 6, 7, 10, 11, 13, 17, 18]90% [1, 2, 4, 6, 7, 1013, 17]
HER2/neu amplification10–30% [1, 4, 10, 17]18–80% [13]
p16 inactivation10% [1, 4, 7, 10, 11]40–45% [4, 7, 10]
E-cadherin loss10–20% [1, 4, 7, 10, 11]60–90% [4]

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.